MORNING BOOST: Women who are “larks” and at their best early in the morning are less likely to develop breast cancer than their night-owl sisters, a study has found. The researchers who compared data on hundreds of thousands of women found that those with an in-built morning preference were 40%-48% less at risk of breast cancer. Part of the analysis also showed that women who slept longer than the recommended seven to eight hours per night increased their chances of being diagnosed by 20% per additional hour spent asleep. Lead scientist Dr Rebecca Richmond, from the University of Bristol, said; “The findings of a protective effect of morning preference on breast cancer risk in our study are consistent with previous research highlighting a role for night shift work and exposure to ‘light-at-night’ as risk factors for breast cancer.” SCREEN TIME: Findings from the Oxford Internet Institute at the University of Oxford found that every hour school age children spent on digital devices only equated to between three and eight fewer minutes of sleep each night. The research, titled Digital Screen Time and Paediatric Sleep and published in the Journal of Pediatrics, found that teenagers who abstain from technology got an average of eight hours and 51 minutes of sleep a night. However, teenagers spending eight hours each day on screens still managed an average of eight hours and 21 minutes of sleep each night. The researchers suggested that other factors relating to family and daily routine possibly should be the focus when trying to get children to sleep better. EARLY PREVENTION: Treating pre-cancerous stem cells at an early stage could be key to preventing bowel cancer in people born with a very high risk of the disease, a study suggests. People with the condition carry a fault in a gene called adenomatous polyposis coli (APC) and have a greater than 95% chance of developing bowel cancer. Scientists found that an existing cancer treatment called Cisplatin could prevent cancer in the mice if used at an early stage. Pre-cancerous stem cells were more sensitive to Cisplatin than normal stem cells in the gut of the mice. The findings were presented at the NCRI Cancer Conference in Glasgow.